(Q37393008)

20 August 2017

1 reference

title

Perifosine: update on a novel Akt inhibitor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957247&resulttype=core&format=json

13 May 2020

author name string

Joell J Gills

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957247&resulttype=core&format=json

13 May 2020

Phillip A Dennis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957247&resulttype=core&format=json

13 May 2020

publication date

1 March 2009

1 reference

20 August 2017

Current Oncology Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957247&resulttype=core&format=json

13 May 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957247&resulttype=core&format=json

13 May 2020

page(s)

102-110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957247&resulttype=core&format=json

13 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957247&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11912-009-0016-4

13 May 2020

exact match

0 references

cites work

A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-009-0016-4

The inhibition of cell signaling pathways by antitumor ether lipids

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-009-0016-4

Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways

21 January 2018

1 reference

12 December 2020

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.

1 reference

12 December 2020

Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells

1 reference

12 December 2020

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

1 reference

12 December 2020

Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors

1 reference

12 December 2020

Pharmacodynamic markers of perifosine efficacy

1 reference

12 December 2020

Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38.

1 reference

12 December 2020

Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model

1 reference

12 December 2020

Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors

1 reference

12 December 2020

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.

1 reference

12 December 2020

Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest

1 reference

12 December 2020

Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts

1 reference

12 December 2020

A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.

1 reference

12 December 2020

Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells.

1 reference

12 December 2020

A phase II study of perifosine in androgen independent prostate cancer

1 reference

12 December 2020

A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells

1 reference

12 December 2020

Perifosine induces differentiation and cell death in prostate cancer cells

1 reference

12 December 2020

Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts.

1 reference

12 December 2020

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment

1 reference

12 December 2020

Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway

1 reference

12 December 2020

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

1 reference

12 December 2020

A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma

1 reference

12 December 2020

Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis

1 reference

12 December 2020

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia

1 reference

12 December 2020

Molecular imaging of Akt kinase activity

1 reference

12 December 2020

Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo

1 reference

12 December 2020

Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation

1 reference

12 December 2020

Targeting Akt in cancer therapy

1 reference

12 December 2020

In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines

1 reference

12 December 2020

A Phase 2 study of perifosine in advanced or metastatic breast cancer.

1 reference

12 December 2020

Phase II study of perifosine in previously untreated patients with metastatic melanoma

1 reference

12 December 2020

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

1 reference

12 December 2020

Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.

1 reference

12 December 2020

Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells

1 reference

12 December 2020

The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial

1 reference

12 December 2020

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

1 reference

12 December 2020

Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid

1 reference

12 December 2020

Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours

1 reference

12 December 2020

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

1 reference

12 December 2020

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation

1 reference

12 December 2020

Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species

1 reference

12 December 2020

The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway

1 reference

12 December 2020

10.1007/S11912-009-0016-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957247&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6957247&resulttype=core&format=json

13 May 2020

1 reference